Suzhou Zelgen Biopharmaceuticals (SHA:688266) resubmitted its application for a secondary offering on the Hong Kong Stock Exchange, according to a Friday disclosure to the Shanghai bourse.
The biopharmaceutical company's offering application filed in December 2025 already lapsed, the Hong Kong bourse said.
Zelgen plans to use proceeds from its planned offering for research and development of its drug candidates and for working capital.